Biotechnology Move in Slovak Rep By Degussa
Not much is heard about the biotechnology industry in the Slovak Republic, but plans by German chemicals/pharmaceutical concern Degussa could change all that. Degussa has said that by the end of 1996 it will have invested around 60 million Deutschemarks ($39.9 million) in extending and renewing existing biotechnology plant at Fermas, a joint venture undertaken by Degussa and the major Slovak antibiotics manufacturer Biotika AS.
Degussa has a 51% stake in this joint venture, established December 1992, and Biotika has 49%. The JV has been in production since early 1993 and already exports to over 20 markets worldwide.
Once the investments in Fermas have been concluded, Degussa, the market leader for methionine, says it will be the only company in the world to supply methionine, lysine, threonine and tryptophan, the amino acids used in animal feed, from a single source.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze